The Filing Desk

Innoviva vs Mirum Pharmaceuticals

Innoviva INVA · Mirum Pharmaceuticals MIRM · Pharmaceuticals

Mirum Pharmaceuticals reported revenue of $521 million in fiscal 2025, 1.3 times Innoviva's $411 million in fiscal 2025. Innoviva's revenue grew 14.7% in its latest year, and Mirum Pharmaceuticals' grew 54.7%. Innoviva had an operating margin of 39.8%, against -4.2% at Mirum Pharmaceuticals. Free cash flow was $196 million at Innoviva and $55 million at Mirum Pharmaceuticals.

Side by side

InnovivaMirum Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$411M$521M
Revenue growth14.7%54.7%
Revenue growth a year, last 5 years4.1%—
Gross margin74.8%—
Operating margin39.8%−4.2%
Net margin65.9%−4.5%
Free cash flow$196M$55M
Free cash flow margin47.6%10.5%
Return on capital17.9%−7.1%
Net debt to EBITDA—−34.9x
Dividends and buybacks$4M$0M
Change in diluted share count14.2%5.6%
Last close$19.03$93.99
P/E at the last close9.5×—
Insider trades, last 12 months—bought $9.0 million, sold $42.9 million
Piotroski F-score6 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
InnovivaMirum Pharmaceuticals
Operating margin
Percent of revenue
InnovivaMirum Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InnovivaMirum Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Innoviva and Mirum Pharmaceuticals pages.